Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro by Omar S. Qureshi, Emma J. Sutton, Rosemary F. Bithell, Shauna M. West, Rona M. Cutler, Gillian McCluskey, Graham Craggs, Asher Maroof, Nicholas M. Barnes, David P. Humphreys, Stephen Rapecki, Bryan J. Smith, Anthony Shock

Get full text

TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life by Emma Davé, Oliver Durrant, Neha Dhami, Joanne Compson, Janice Broadbridge, Sophie Archer, Asher Maroof, Kevin Whale, Karelle Menochet, Pierre Bonnaillie, Emily Barry, Gavin Wild, Claude Peerboom, Pallavi Bhatta, Mark Ellis, Matthew Hinchliffe, David P. Humphreys, Sam P. Heywood

Get full text

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies by Frank R. Brennan, J. Ryan Polli, Jean Sathish, Melissa Ramones, Babette Wolf, Tilman Schlothauer, Shirley J. Peters, Curtis C. Maier, Changhua Ji, David L. Wensel, Derrick Witcher, Patricia C. Ryan, T. Scott Manetz, Adriano Flora, Brian Soper, Birgit Fogal, Lindsey Dzielak, Xiaoting Wang, Prathap Nagaraja Shastri, Karen Price, Michael Doyle, Nidhi Sharda, Mary Struthers, Maximilian Brinkhaus, Bianca Balbino, Eric Stefanich, Masaki Honda, Jan Terje Andersen, Shermaine Mitchell-Ryan, David P. Humphreys

Get full text